We’re delighted to be working with colleagues at The Newcastle Upon Tyne Hospitals NHS Foundation Trust NovoPath NCL laboratory and RareCan on an innovative research programme, which is playing a vital role in developing treatments for rarer forms of cancer.
The Novopath team is using their expertise, specialist facilities and advanced techniques to prepare and store slides containing rare cancer samples, ready for further analysis by researchers.
RareCan is connecting consenting patients with these leading researchers and arranging access to the tissue, blood samples and genetic data that our lab team is helping to prepare.
Alastair Burt from NovoPath says the specialist team and laboratory “…provides a dedicated service to improve diagnostics and precision medicine, in particular for cancer treatment and inflammatory diseases.
“In addition to providing high quality samples, our scientists can offer researchers access to services such as tissue micro arrays, DNA extraction and advanced imaging of tissue.
”We’re really excited about our partnership with RareCan and the role we’ll play in supporting patients and researchers across the whole of the UK.”
#rarecancers collectively affect more than 70,000 people each year in the UK, which is more than 1 in 5 of total cancer diagnoses. About two thirds will die from their disease within five years, compared with under half for those affected by common cancers.
Full details can be found on the following link – https://www.linkedin.com/feed/update/urn:li:activity:6874744921736261632/
A article has also been highlighted on the North East England Chamber of Commerce – https://www.neechamber.co.uk/view/M_News_HOSP012_11_12_2021_11_06_48/